Developer docs
API playgroundTry for free, no card

Search company profiles

Scorpion Therapeutics

Full company profile

uuid00033rh

Namestring
Scorpion Therapeutics
Legal namestring
Scorpion Therapeutics, Inc.
Websiteurl
scorpiontx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Scorpion Therapeutics, Inc. was a clinical-stage precision oncology company founded in 2020 and headquartered in Boston, Massachusetts. The company focused on discovering and developing small molecule targeted therapies for cancer patients, with particular emphasis on well-validated but previously undruggable targets. Its lead clinical asset, STX-478, was a once-daily oral, mutant-selective PI3Kα inhibitor designed to selectively target the PI3Kα pathway in cancerous cells while sparing healthy cells, addressing a key tolerability limitation of currently approved PI3Kα inhibitors. STX-478 was being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors driven by PI3Kα mutations, with the addressable patient population estimated at 30-40% of hormone-positive breast cancer patients.

The company built a proprietary, fully-integrated discovery platform combining cancer biology, medicinal chemistry, and data sciences to produce its pipeline of three internally discovered clinical candidates and multiple discovery-stage programs. Scorpion operated as a venture-backed private biotechnology company, raising approximately $420M across three private financing rounds between 2020 and 2024, and employed 101-250 people. The company had no commercialized products and no product revenue; its business model centered on R&D and clinical development funded by equity capital, with value realization occurring through strategic transactions.

In January 2025, Eli Lilly and Company agreed to acquire Scorpion's PI3Kα inhibitor program for up to $2.5 billion in cash, inclusive of upfront and regulatory/sales milestone payments. As part of the transaction, Scorpion spun out a new entity — Antares Therapeutics — to retain its employees and non-PI3Kα pipeline assets, with Lilly taking a minority equity interest. Antares subsequently launched with a $177 million Series A round and entered a partnership with Novartis to advance its covalent drug discovery engine and broader precision oncology pipeline.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
precision oncology therapies, small molecule drug discovery, PI3Kα inhibitor development, targeted cancer therapeutics, mutant-selective oncology
Industry2 codes
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Pharmaceuticals
Social media profiles1 record
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Scorpion Therapeutics is a clinical-stage precision oncology company that develops small molecule targeted therapies for cancer patients. Its lead program, STX-478, is a once-daily oral, mutant-selective PI3Kα inhibitor in Phase 1/2 clinical trials for breast cancer and other advanced solid tumors driven by PI3Kα mutations. The company also maintains multiple discovery-stage programs targeting previously undruggable oncology targets using its integrated cancer biology, medicinal chemistry, and data sciences discovery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Potentially addresses 30-40% of hormone-positive breast cancer patients with PI3Kα mutations
Product overview1 text field

Scorpion Therapeutics is a clinical-stage precision oncology company that developed targeted therapies for patients with cancer. The company's pipeline was led by STX-478, a mutant-selective PI3Kα inhibitor, and included three internally discovered clinical product candidates plus multiple discovery-stage programs. Eli Lilly acquired Scorpion's PI3Kα inhibitor program for up to $2.5 billion in January 2025, while a new spun-out entity retained the non-PI3Kα pipeline assets. Scorpion built proprietary and fully-integrated discovery capabilities leveraging advanced technologies across cancer biology, medicinal chemistry, and data sciences to develop product candidates selective against previously undruggable targets.

Product and service1 record
1STX-478
CategoryClinical-stage drug candidate (oncology small molecule)
Description

Once-daily oral, mutant-selective PI3Kα inhibitor in Phase 1/2 clinical development for hormone-positive breast cancer and other advanced solid tumors carrying PI3Kα mutations; selectively targets the PI3Kα pathway in cancerous cells while sparing healthy cells, intended to address approximately 30-40% of hormone-positive breast cancer patients.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

Eli Lilly acquired Scorpion's mutant-selective PI3Kα inhibitor program including STX-478 for up to $2.5 billion. Lilly gained options that could bring milestones plus tiered royalties. As part of the transaction, Scorpion spun out a new entity to hold employees and non-PI3Kα pipeline assets, with Lilly holding a minority equity interest in the new company.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Revolution Medicines is a clinical-stage precision oncology company developing targeted small molecule therapies against RAS and other oncogenic drivers. It shares Scorpion's focus on difficult, previously undruggable oncology targets and integrated drug discovery.

TypeBroad incumbent
Description

Mirati Therapeutics developed targeted oncology therapies including Krazati (adagrasib) and was acquired by BMS. It is a broad incumbent in precision oncology with overlapping development of mutant-selective oncology drugs and similar exit profile to Scorpion.

TypeBroad incumbent
Description

Roche developed inavolisib (Itovebi), a more recent PI3Kα inhibitor approved in HR+ breast cancer, and represents the current best-in-class benchmark that STX-478 must beat on tolerability and efficacy in the same indication.

TypeDirect peer
Description

Black Diamond Therapeutics is a precision oncology company developing small molecule therapies against allosteric and mutant oncogenic targets, including in the PI3K and MAPK pathways. It is a direct comparator in the mutant-selective oncology space.

TypeDirect peer
Description

Relay Therapeutics developed RLY-2608, a mutant-selective PI3Kα inhibitor and one of Scorpion's closest direct competitors in precision PI3Kα oncology. Both companies pursue structure-based drug design of mutant-selective inhibitors against validated oncology targets.

6Nuvalent
TypeDirect peer
Description

Nuvalent is a clinical-stage precision oncology company designing small molecule kinase and other targeted inhibitors using an integrated chemistry, biology, and computational approach. Its pipeline profile and discovery philosophy closely mirror Scorpion's model of selective kinase targeting.

TypeBroad incumbent
Description

Novartis commercializes alpelisib (Piqray), the first approved PI3Kα inhibitor, and is a direct comparator in the PI3Kα commercial landscape where STX-478 will compete. It is also partnered with Antares Therapeutics post-spinout.

TypeDirect peer
Description

Foghorn Therapeutics is a clinical-stage precision oncology company developing therapies targeting the chromatin regulatory system. It is comparable to Scorpion as a clinical-stage biotech leveraging proprietary platforms against previously undruggable oncology targets.

TypeBroad incumbent
Description

Eli Lilly is the strategic acquirer of Scorpion's PI3Kα program and now serves as the parent commercializing STX-478. It is a broad incumbent in oncology with the global infrastructure necessary to scale STX-478 globally.

TypeEmerging player
Description

Nested Therapeutics is an early-stage precision oncology company applying computational chemistry to discover small molecule inhibitors against oncogenic targets. It is comparable as an emerging player pursuing precision small molecule oncology with a similar platform-driven approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scorpion Therapeutics

Precision Oncology Pharmaceuticalsscorpiontx.com

What Scorpion Therapeutics does

Scorpion Therapeutics, Inc. was a clinical-stage precision oncology company founded in 2020 and headquartered in Boston, Massachusetts. The company focused on discovering and developing small molecule targeted therapies for cancer patients, with particular emphasis on well-validated but previously undruggable targets. Its lead clinical asset, STX-478, was a once-daily oral, mutant-selective PI3Kα inhibitor designed to selectively target the PI3Kα pathway in cancerous cells while sparing healthy cells, addressing a key tolerability limitation of currently approved PI3Kα inhibitors. STX-478 was being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors driven by PI3Kα mutations, with the addressable patient population estimated at 30-40% of hormone-positive breast cancer patients.

The company built a proprietary, fully-integrated discovery platform combining cancer biology, medicinal chemistry, and data sciences to produce its pipeline of three internally discovered clinical candidates and multiple discovery-stage programs. Scorpion operated as a venture-backed private biotechnology company, raising approximately $420M across three private financing rounds between 2020 and 2024, and employed 101-250 people. The company had no commercialized products and no product revenue; its business model centered on R&D and clinical development funded by equity capital, with value realization occurring through strategic transactions.

In January 2025, Eli Lilly and Company agreed to acquire Scorpion's PI3Kα inhibitor program for up to $2.5 billion in cash, inclusive of upfront and regulatory/sales milestone payments. As part of the transaction, Scorpion spun out a new entity — Antares Therapeutics — to retain its employees and non-PI3Kα pipeline assets, with Lilly taking a minority equity interest. Antares subsequently launched with a $177 million Series A round and entered a partnership with Novartis to advance its covalent drug discovery engine and broader precision oncology pipeline.

Scorpion Therapeutics firmographics

Firmographics
Name
Scorpion Therapeutics
Legal name
Scorpion Therapeutics, Inc.
Website
https://scorpiontx.com
Company type
Private
Founded year
2020
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

Scorpion Therapeutics industry classification

Industry
Product category
Precision Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Precision oncology therapies
  • Small molecule drug discovery
  • PI3Kα inhibitor development
  • Targeted cancer therapeutics
  • Mutant-selective oncology

Where Scorpion Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Scorpion Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

Distribution channels1 record

Marketing channels2 records

Scorpion Therapeutics product offering

Product offering

Core offering

Scorpion Therapeutics is a clinical-stage precision oncology company that develops small molecule targeted therapies for cancer patients. Its lead program, STX-478, is a once-daily oral, mutant-selective PI3Kα inhibitor in Phase 1/2 clinical trials for breast cancer and other advanced solid tumors driven by PI3Kα mutations. The company also maintains multiple discovery-stage programs targeting previously undruggable oncology targets using its integrated cancer biology, medicinal chemistry, and data sciences discovery platform.

Product overview

Scorpion Therapeutics is a clinical-stage precision oncology company that developed targeted therapies for patients with cancer. The company's pipeline was led by STX-478, a mutant-selective PI3Kα inhibitor, and included three internally discovered clinical product candidates plus multiple discovery-stage programs. Eli Lilly acquired Scorpion's PI3Kα inhibitor program for up to $2.5 billion in January 2025, while a new spun-out entity retained the non-PI3Kα pipeline assets. Scorpion built proprietary and fully-integrated discovery capabilities leveraging advanced technologies across cancer biology, medicinal chemistry, and data sciences to develop product candidates selective against previously undruggable targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • STX-478 Once-daily oral, mutant-selective PI3Kα inhibitor in Phase 1/2 clinical development for hormone-positive breast cancer and other advanced solid tumors carrying PI3Kα mutations; selectively targets the PI3Kα pathway in cancerous cells while sparing healthy cells, intended to address approximately 30-40% of hormone-positive breast cancer patients.

Quantifiable outcome

  • Potentially addresses 30-40% of hormone-positive breast cancer patients with PI3Kα mutations

Companies that use Scorpion Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Scorpion Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Scorpion Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 13 January 2025Eli Lilly acquired Scorpion's mutant-selective PI3Kα inhibitor program including STX-478 for up to $2.5 billion. Lilly gained options that could bring milestones plus tiered royalties. As part of the transaction, Scorpion spun out a new entity to hold employees and non-PI3Kα pipeline assets, with Lilly holding a minority equity interest in the new company.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Scorpion Therapeutics competitors and assessment

Company assessment

Direct peers

  • Revolution Medicines: Revolution Medicines is a clinical-stage precision oncology company developing targeted small molecule therapies against RAS and other oncogenic drivers. It shares Scorpion's focus on difficult, previously undruggable oncology targets and integrated drug discovery.
  • Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology company developing small molecule therapies against allosteric and mutant oncogenic targets, including in the PI3K and MAPK pathways. It is a direct comparator in the mutant-selective oncology space.
  • Relay Therapeutics: Relay Therapeutics developed RLY-2608, a mutant-selective PI3Kα inhibitor and one of Scorpion's closest direct competitors in precision PI3Kα oncology. Both companies pursue structure-based drug design of mutant-selective inhibitors against validated oncology targets.
  • Nuvalent: Nuvalent is a clinical-stage precision oncology company designing small molecule kinase and other targeted inhibitors using an integrated chemistry, biology, and computational approach. Its pipeline profile and discovery philosophy closely mirror Scorpion's model of selective kinase targeting.
  • Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage precision oncology company developing therapies targeting the chromatin regulatory system. It is comparable to Scorpion as a clinical-stage biotech leveraging proprietary platforms against previously undruggable oncology targets.

Broad incumbents

  • Mirati Therapeutics: Mirati Therapeutics developed targeted oncology therapies including Krazati (adagrasib) and was acquired by BMS. It is a broad incumbent in precision oncology with overlapping development of mutant-selective oncology drugs and similar exit profile to Scorpion.
  • Roche: Roche developed inavolisib (Itovebi), a more recent PI3Kα inhibitor approved in HR+ breast cancer, and represents the current best-in-class benchmark that STX-478 must beat on tolerability and efficacy in the same indication.
  • Novartis: Novartis commercializes alpelisib (Piqray), the first approved PI3Kα inhibitor, and is a direct comparator in the PI3Kα commercial landscape where STX-478 will compete. It is also partnered with Antares Therapeutics post-spinout.
  • Eli Lilly: Eli Lilly is the strategic acquirer of Scorpion's PI3Kα program and now serves as the parent commercializing STX-478. It is a broad incumbent in oncology with the global infrastructure necessary to scale STX-478 globally.

Emerging players

  • Nested Therapeutics: Nested Therapeutics is an early-stage precision oncology company applying computational chemistry to discover small molecule inhibitors against oncogenic targets. It is comparable as an emerging player pursuing precision small molecule oncology with a similar platform-driven approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Scorpion Therapeutics social profiles

Digital presence

Scorpion Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scorpion Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Scorpion Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Scorpion Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scorpion Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scorpion Therapeutics

What does Scorpion Therapeutics do?

Scorpion Therapeutics is a clinical-stage precision oncology company that develops small molecule targeted therapies for cancer patients. Its lead program, STX-478, is a once-daily oral, mutant-selective PI3Kα inhibitor in Phase 1/2 clinical trials for breast cancer and other advanced solid tumors driven by PI3Kα mutations. The company also maintains multiple discovery-stage programs targeting previously undruggable oncology targets using its integrated cancer biology, medicinal chemistry, and data sciences discovery platform.

Is Scorpion Therapeutics a public or private company?

Scorpion Therapeutics is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Scorpion Therapeutics founded?

Scorpion Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Scorpion Therapeutics based?

Scorpion Therapeutics is headquartered in Boston, United States, in the North America region.

Who are Scorpion Therapeutics's main competitors?

Direct peers on record are Revolution Medicines, Black Diamond Therapeutics, Relay Therapeutics, Nuvalent and Foghorn Therapeutics. Broad incumbents are Mirati Therapeutics, Roche, Novartis and Eli Lilly. Nested Therapeutics is listed as an emerging player.

Does Scorpion Therapeutics have an API?

No public API is recorded for Scorpion Therapeutics.

What industry is Scorpion Therapeutics in?

Scorpion Therapeutics's product category is Precision Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cascade-PartnersOncology at an Inflection Point: How Clinical Innovation is Fueling a New Wave of M&ATherapeutic innovation in precision medicine, immunotherapy, and cell therapies is driving accelerated consolidation across the oncology sector, with the global market projected to grow over 7% annually through 2033 and outpatient infusion services expected to expand at 11%. Notable transactions include Cencora's $7.4 billion acquisition of OneOncology (December 2025), Eli Lilly's $2.5 billion purchase of Scorpion Therapeutics (March 2025), Novartis's $1 billion acquisition of Mariana Oncology (May 2024), and University of Iowa Health Care's $280 million acquisition of Mission Cancer + Blood (December 2024). The convergence of capital-intensive care models, reimbursement complexity, and fragmented market structure is drawing private equity, hospital systems, drug distributors, and insurers into active consolidation, positioning scaled platforms with integrated pharmacy, diagnostics, and research capabilities for sustained growth through the next decade.SCILife sciences and pharma priorities in 2025: M&A, AI and ChinaA 2025 industry outlook indicates a resurgence in M&A activity for life sciences companies, driven by $1.3 trillion in available capital and impending patent expiries that threaten $300 billion in revenue by 2028. Major players are shifting focus toward earlier-stage innovation, AI partnerships, and Chinese biotech assets to offset these challenges. Recent high-profile transactions include Johnson & Johnson's acquisition of Intra-Cellular Therapies and Eli Lilly's deal with Scorpion Therapeutics.Towards HealthcarePrecision Oncology Market Size Boosts 9.9% CAGR by 2034The global precision oncology market is projected to grow from $120.9 billion in 2024 to $310.75 billion by 2034, driven by rising cancer prevalence and demand for personalized medicine. Key industry developments include strategic collaborations between COTA, Inc. and Guardant Health, the expansion of Caris Life Sciences' alliances, and significant funding rounds for Scorpion Therapeutics.openPR.comThyroid Cancer Treatment Market 2025 | Latest FDA Approvals, M&A Deals & Research Updates, Clinical Phases - Key Industry Players are Genentech USA, Inc, Blueprint Medicines Corporation, Daiichi SankyThe global thyroid cancer treatment market is projected to grow from US$1.14 billion in 2024 to US$2.94 billion by 2033, a CAGR of 11.2%. Recent M&A activity includes GSK's $1.15 billion acquisition of IDRx and Eli Lilly's $2.5 billion deal for Scorpion Therapeutics, while FDA approvals for cabozantinib and lenvatinib-pembrolizumab are noted.DealformaCancer R&D Partnerships, M&A and Venture Funding Activity by TAQ1 2025 saw robust cancer R&D activity with 63 partnership deals totaling $21.4 billion and 22 M&A transactions worth $15.3 billion, reflecting a shift toward more upfront payments ($12.8 billion paid immediately). Major deals included AstraZeneca's $4.4 billion platform partnership with Harbour BioMed, Merck KGaA's $3.5 billion acquisition of SpringWorks, and Eli Lilly's $2.5 billion purchase of Scorpion Therapeutics' PI3Kα inhibitor program, while venture funding saw 54 rounds raising $2.2 billion led by Eikon Therapeutics' $351 million series D.NasdaqThe Unstoppable Momentum in Oncology M&AEli Lilly is in advanced talks to acquire Scorpion Therapeutics for up to $2.5 billion, with about $1 billion upfront. GSK acquired IDRx for up to $1.15 billion, focusing on rare cancer therapies. The deals reflect a broader oncology M&A trend driven by financial strength and innovation.BloombergLilly Sells $6.5 Billion of Bonds for Cancer Drug PurchaseEli Lilly sold $6.5 billion of bonds in six parts to finance a $2.5 billion purchase of a cancer drug from Scorpion Therapeutics. The longest portion, a 40-year note, yields 0.9 percentage points over Treasuries, with initial price talk around 1.15 percentage points.PR NewswireLilly reports full Q4 2024 financial results and provides 2025 guidanceEli Lilly reported Q4 2024 revenue of $13.53 billion, up 45% year-over-year, with EPS of $4.88 reported and $5.32 non-GAAP. The company issued 2025 guidance of $58-61 billion revenue and $22.05-23.55 EPS. It also noted FDA approvals for Zepbound and Omvoh, and a pending acquisition of Scorpion Therapeutics.Seeking AlphaJ.P. Morgan Healthcare Conference 2025: Healthcare's Roadmap For The Year AheadThe 2025 J.P. Morgan Healthcare Conference highlighted renewed M&A activity, including Johnson & Johnson's $14.6B acquisition of Intra-Cellular Therapeutics and Eli Lilly's $2.5B deal for Scorpion Therapeutics. Industry leaders cited nearly $1T in combined financial capacity and AI integration to address a projected 10 million worker shortfall by 2030.AxiosSigns of optimism for biopharma at JPM conferencePharmaceutical companies and biotech firms are expressing cautious optimism about an uptick in dealmaking at the 2025 J.P. Morgan Healthcare Conference in San Francisco, following several years of subdued activity due to inflation, high borrowing costs, and regulatory uncertainty. Major deals announced at the conference include Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular, Eli Lilly's $2.5 billion purchase of Scorpion Therapeutics, and GlaxoSmithKline's $1 billion-plus deal for IDRx, with analysts expecting continued M&A momentum as the Federal Trade Commission is anticipated to take a more relaxed stance. However, some caution remains as analysts predict smaller deal sizes overall, and Moderna recently slashed its 2025 sales forecast due to uncertainty around its COVID and RSV products.